Need professional-grade analysis? Visit stockanalysis.com
$83.32M
N/A
N/A
N/A
Verrica Pharmaceuticals Inc (VRCA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $6.50, up 2.93% from the previous close.
Over the past year, VRCA has traded between a low of $3.28 and a high of $9.10. The stock has gained 41.8% over this period. It is currently 28.5% below its 52-week high.
Verrica Pharmaceuticals Inc has a market capitalization of $83.32M.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Side-by-side comparison against top Healthcare peers.